Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100178369> ?p ?o ?g. }
- W2100178369 endingPage "2243" @default.
- W2100178369 startingPage "2243" @default.
- W2100178369 abstract "Pentavalent rotavirus vaccine (RV5), a live, oral attenuated vaccine, prevented 98% of severe rotavirus diarrhea in a trial conducted mainly in Finland and the United States. Nicaragua introduced RV5 in 2006, providing the first opportunity to assess the association between vaccination and rotavirus disease in a developing country.To assess the association between RV5 vaccination and subsequent rotavirus diarrhea requiring overnight admission or intravenous hydration.Case-control evaluation in 4 hospitals in Nicaragua from June 2007 to June 2008. Cases were children age-eligible to receive RV5 who were admitted or required intravenous hydration for laboratory-confirmed rotavirus diarrhea. For each case (n = 285), 1 to 3 neighborhood (n = 840) and hospital (n = 690) controls were selected.Primary outcome was the association of RV5 and rotavirus diarrhea requiring overnight admission or intravenous hydration in the emergency department. Secondary analysis further classified disease as severe and very severe. We computed the matched odds ratio of vaccination in cases vs controls. Vaccine effectiveness was estimated using the formula 1 - matched odds ratio x 100%.Of the 285 rotavirus cases, 265 (93%) required hospitalization; 251 (88%) received intravenous hydration. A single rotavirus strain (G2P[4]) was identified in 88% of the cases. Among cases and controls, respectively, 18% and 12% were unvaccinated, 12% and 15% received 1 dose of RV5, 15% and 17% received 2 doses, and 55% and 57% received 3 doses. Vaccination with 3 doses was associated with a lower risk of rotavirus diarrhea requiring overnight admission or intravenous hydration (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.36-0.82). Of the 285 rotavirus cases, 191 (67%) were severe and 54 (19%) were very severe. A progressively lower risk of severe (OR, 0.42; 95% CI, 0.26-0.70) and very severe rotavirus diarrhea (OR, 0.23; 95% CI, 0.08-0.61) was observed after RV5 vaccination. Thus, effectiveness of 3 doses of RV5 against rotavirus disease requiring admission or treatment with intravenous hydration was 46% (95% CI, 18%-64%); against severe rotavirus diarrhea, 58% (95% CI, 30%-74%); and against very severe rotavirus diarrhea, 77% (95% CI, 39%-92%).Vaccination with RV5 was associated with a lower risk of severe rotavirus diarrhea in children younger than 2 years in Nicaragua but to a lesser extent than that seen in clinical trials in industrialized countries." @default.
- W2100178369 created "2016-06-24" @default.
- W2100178369 creator A5087750390 @default.
- W2100178369 date "2009-06-03" @default.
- W2100178369 modified "2023-09-25" @default.
- W2100178369 title "Association Between Pentavalent Rotavirus Vaccine and Severe Rotavirus Diarrhea Among Children in Nicaragua" @default.
- W2100178369 cites W1637418879 @default.
- W2100178369 cites W1650197172 @default.
- W2100178369 cites W1905404445 @default.
- W2100178369 cites W1952903862 @default.
- W2100178369 cites W1973948212 @default.
- W2100178369 cites W1974822017 @default.
- W2100178369 cites W1979410289 @default.
- W2100178369 cites W1985494124 @default.
- W2100178369 cites W2000093434 @default.
- W2100178369 cites W2006763045 @default.
- W2100178369 cites W2011038561 @default.
- W2100178369 cites W2025454977 @default.
- W2100178369 cites W2027227419 @default.
- W2100178369 cites W2028814069 @default.
- W2100178369 cites W2032614954 @default.
- W2100178369 cites W2037011441 @default.
- W2100178369 cites W2054126241 @default.
- W2100178369 cites W2057022620 @default.
- W2100178369 cites W2072881891 @default.
- W2100178369 cites W2077128987 @default.
- W2100178369 cites W2084653854 @default.
- W2100178369 cites W2087155029 @default.
- W2100178369 cites W2093323646 @default.
- W2100178369 cites W2095820230 @default.
- W2100178369 cites W2099902534 @default.
- W2100178369 cites W2101154874 @default.
- W2100178369 cites W2104362710 @default.
- W2100178369 cites W2114868420 @default.
- W2100178369 cites W2127653958 @default.
- W2100178369 cites W2137908328 @default.
- W2100178369 cites W2143233237 @default.
- W2100178369 cites W2155458310 @default.
- W2100178369 cites W2158450124 @default.
- W2100178369 cites W2160509578 @default.
- W2100178369 cites W2169694950 @default.
- W2100178369 cites W2170749337 @default.
- W2100178369 cites W2180846871 @default.
- W2100178369 cites W2336472430 @default.
- W2100178369 doi "https://doi.org/10.1001/jama.2009.756" @default.
- W2100178369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19491186" @default.
- W2100178369 hasPublicationYear "2009" @default.
- W2100178369 type Work @default.
- W2100178369 sameAs 2100178369 @default.
- W2100178369 citedByCount "238" @default.
- W2100178369 countsByYear W21001783692012 @default.
- W2100178369 countsByYear W21001783692013 @default.
- W2100178369 countsByYear W21001783692014 @default.
- W2100178369 countsByYear W21001783692015 @default.
- W2100178369 countsByYear W21001783692016 @default.
- W2100178369 countsByYear W21001783692017 @default.
- W2100178369 countsByYear W21001783692018 @default.
- W2100178369 countsByYear W21001783692019 @default.
- W2100178369 countsByYear W21001783692020 @default.
- W2100178369 countsByYear W21001783692021 @default.
- W2100178369 countsByYear W21001783692022 @default.
- W2100178369 countsByYear W21001783692023 @default.
- W2100178369 crossrefType "journal-article" @default.
- W2100178369 hasAuthorship W2100178369A5087750390 @default.
- W2100178369 hasConcept C126322002 @default.
- W2100178369 hasConcept C156957248 @default.
- W2100178369 hasConcept C187212893 @default.
- W2100178369 hasConcept C203014093 @default.
- W2100178369 hasConcept C22070199 @default.
- W2100178369 hasConcept C2777227250 @default.
- W2100178369 hasConcept C2779802037 @default.
- W2100178369 hasConcept C2781367151 @default.
- W2100178369 hasConcept C44249647 @default.
- W2100178369 hasConcept C71924100 @default.
- W2100178369 hasConceptScore W2100178369C126322002 @default.
- W2100178369 hasConceptScore W2100178369C156957248 @default.
- W2100178369 hasConceptScore W2100178369C187212893 @default.
- W2100178369 hasConceptScore W2100178369C203014093 @default.
- W2100178369 hasConceptScore W2100178369C22070199 @default.
- W2100178369 hasConceptScore W2100178369C2777227250 @default.
- W2100178369 hasConceptScore W2100178369C2779802037 @default.
- W2100178369 hasConceptScore W2100178369C2781367151 @default.
- W2100178369 hasConceptScore W2100178369C44249647 @default.
- W2100178369 hasConceptScore W2100178369C71924100 @default.
- W2100178369 hasIssue "21" @default.
- W2100178369 hasLocation W21001783691 @default.
- W2100178369 hasLocation W21001783692 @default.
- W2100178369 hasOpenAccess W2100178369 @default.
- W2100178369 hasPrimaryLocation W21001783691 @default.
- W2100178369 hasRelatedWork W177482671 @default.
- W2100178369 hasRelatedWork W1915195247 @default.
- W2100178369 hasRelatedWork W1978357978 @default.
- W2100178369 hasRelatedWork W2075257077 @default.
- W2100178369 hasRelatedWork W2100178369 @default.
- W2100178369 hasRelatedWork W2111991249 @default.
- W2100178369 hasRelatedWork W2269467267 @default.
- W2100178369 hasRelatedWork W2896815815 @default.
- W2100178369 hasRelatedWork W4226266546 @default.